Literature DB >> 26739610

Invasive Candidiasis.

Todd P McCarty1, Peter G Pappas2.   

Abstract

Invasive candidiasis is a collective term that refers to a group of infectious syndromes caused by a variety of species of Candida, 5 of which cause most cases. Candidemia is the most commonly recognized syndrome associated with invasive candidiasis. Certain conditions may influence the likelihood for one species versus another in a specific clinical scenario, and this can have important implications for selection of antifungal therapy and the duration of treatment. Molecular diagnostic technology plays an ever-increasing role as an adjunct to traditional culture-based diagnostics, offering significant potential toward improvement in patient care.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antifungals; Bloodstream infection; Candida; Fungal infection; Invasive candidiasis

Mesh:

Substances:

Year:  2015        PMID: 26739610     DOI: 10.1016/j.idc.2015.10.013

Source DB:  PubMed          Journal:  Infect Dis Clin North Am        ISSN: 0891-5520            Impact factor:   5.982


  81 in total

1.  Transcription factor network efficiency in the regulation of Candida albicans biofilms: it is a small world.

Authors:  Virginia E Glazier; Damian J Krysan
Journal:  Curr Genet       Date:  2018-01-09       Impact factor: 3.886

2.  Economic evaluation of micafungin versus liposomal amphotericin B (LAmB) for treating patients with candidaemia and invasive candidiasis (IC) in Turkey.

Authors:  Chin Fen Neoh; Esin Senol; Ates Kara; Ener Cagri Dinleyici; Stuart J Turner; David C M Kong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2018-06-30       Impact factor: 3.267

3.  Pharmacoeconomic evaluation of micafungin versus caspofungin as definitive therapy for candidaemia and invasive candidiasis (IC) in Turkey.

Authors:  C F Neoh; E Senol; A Kara; E C Dinleyici; S J Turner; D C M Kong
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2017-11-28       Impact factor: 3.267

Review 4.  Combinatorial strategies for combating invasive fungal infections.

Authors:  Michaela Spitzer; Nicole Robbins; Gerard D Wright
Journal:  Virulence       Date:  2016-06-07       Impact factor: 5.882

5.  Screening the Pathogen Box for Identification of Candida albicans Biofilm Inhibitors.

Authors:  Taissa Vila; Jose L Lopez-Ribot
Journal:  Antimicrob Agents Chemother       Date:  2016-12-27       Impact factor: 5.191

Review 6.  Human inborn errors of immunity underlying superficial or invasive candidiasis.

Authors:  Anne Puel
Journal:  Hum Genet       Date:  2020-03-02       Impact factor: 4.132

7.  Effect of Antifungal Treatment in a Diet-Based Murine Model of Disseminated Candidiasis Acquired via the Gastrointestinal Tract.

Authors:  David Kadosh; Laura K Najvar; Rosie Bocanegra; Marcos Olivo; William R Kirkpatrick; Nathan P Wiederhold; Thomas F Patterson
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

8.  Complex Haploinsufficiency-Based Genetic Analysis of the NDR/Lats Kinase Cbk1 Provides Insight into Its Multiple Functions in Candida albicans.

Authors:  Sarah Saputo; Kaitlyn L Norman; Thomas Murante; Brooke N Horton; Jacinto De La Cruz Diaz; Louis DiDone; Jennifer Colquhoun; Jeremy W Schroeder; Lyle A Simmons; Anuj Kumar; Damian J Krysan
Journal:  Genetics       Date:  2016-05-20       Impact factor: 4.562

9.  Post-sepsis immunosuppression depends on NKT cell regulation of mTOR/IFN-γ in NK cells.

Authors:  Edy Y Kim; Hadas Ner-Gaon; Jack Varon; Aidan M Cullen; Jingyu Guo; Jiyoung Choi; Diana Barragan-Bradford; Angelica Higuera; Mayra Pinilla-Vera; Samuel Ap Short; Antonio Arciniegas-Rubio; Tomoyoshi Tamura; David E Leaf; Rebecca M Baron; Tal Shay; Michael B Brenner
Journal:  J Clin Invest       Date:  2020-06-01       Impact factor: 14.808

Review 10.  Targeting Candida albicans filamentation for antifungal drug development.

Authors:  Taissa Vila; Jesus A Romo; Christopher G Pierce; Stanton F McHardy; Stephen P Saville; José L Lopez-Ribot
Journal:  Virulence       Date:  2016-06-07       Impact factor: 5.882

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.